Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

AbCellera Biologics Q3 2026 Results: Net Loss of $40.8M, Loss Narrows

AbCellera Biologics Inc. reported total revenue of $23.0 million for the nine months ended September 30, 2026, a decrease from $30.3 million in the prior year period. The company recorded a net loss of $151.3 million for the first nine months of 2026, driven by significant research and development expenses of $136.2 million as it advances its internal drug candidate pipeline, including ABCL635.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue10.69.0
Profit before tax-42.8-68.8
Net income-40.8-57.1
EPS (diluted, $ a share)$-0.13$-0.19

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+18.8%
Source

10-Q filed with the SEC, NASDAQ: ABCL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

AbCellera Biologics Inc.: key numbers

Share price
$11.12Close, Nov 16
Market cap
$3.63B
Shares outstanding
326.62MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from AbCellera Biologics Inc.

All →
12:41 PM ET Form 4
Insider Buying

AbCellera Biologics CFO Andrew Booth Buys $97.4K of Stock

Andrew Booth, CFO, bought 8,600 shares of AbCellera Biologics Inc. at $11.33 a share, worth $97.4K in total on Nov 13, 2026. Shares held after the trade: 491,400 (+1.8%).

Value
$97.4K
Shares
8,600
Price
$11.33
Role
CFO
Holding change
+1.8%
Trade date
Nov 13, 2026
1:15 PM ET Form 4
Insider Buying

AbCellera Biologics Insider Thermopylae Holdings Ltd. Buys $699K of Stock

Thermopylae Holdings Ltd. bought 60,565 shares of AbCellera Biologics Inc. at $11.54 a share, worth $699K in total on Nov 12, 2026. Shares held after the trade: 56,194,662 (+0.1%).

Value
$699K
Shares
60,565
Price
$11.54
Holding change
+0.1%
Trade date
Nov 12, 2026
4:23 PM ET 8-K
Financial Results

AbCellera Biologics Financial Results

AbCellera reported Q3 2026 financial results with revenue of $10.6 million and a net loss of $40.8 million. The company highlighted positive Phase 2 data for its ABCL635 program and a $200 million capital raise that increased total liquidity to approximately $890 million.

Term
Q3 2026

“This was a transformative quarter for AbCellera, highlighted by strong clinical execution and balance sheet expansion. Positive top-line Phase 2 results for ABCL635 demonstrated an efficacy and tolerability profile that has potential to redefine the treatment of hot flashes.”

Carl Hansen, Ph.D., founder and CEO of AbCellera

“On the strength of this data, we raised $200 million, bringing our available liquidity to approximately $900 million. Together with the top-line Phase 1 readout of ABCL575 and the addition of three new pipeline programs, ABCL992, ABCL385, and ABCL646, we have delivered on all corporate priorities for 2026.”

Carl Hansen, Ph.D., founder and CEO of AbCellera

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.